SEC Form 4 · accession 0001104659-18-001524
SUPERNUS PHARMACEUTICALS, INC. · SUPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Victor Vaughn
Officer — Sr. VP of Sales
Period of report
Jan 9, 2018
Accepted (ET)
Jan 9, 2018 · 7:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001356576
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 9, 2018 | M | 15,000 | $7.90 | A | 24,344 | D | |
| Common StockF2 | Jan 9, 2018 | S | 15,000 | $42.0433 | D | 9,344 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F3 | $7.90 | Jan 9, 2018 | M | 15,000 | D | — | Feb 5, 2023 | Common Stock | 15,000 | 15,000 | D |
Explanation of responses
- F1Transaction made pursuant to a Rule 10b5-1 trading plan adopted November 21, 2017.
- F2The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $42.0000 to $42.4000, inclusive. The reporting person undertakes to provide to Supernus Pharmaceuticals, Inc. ("Supernus"), any security holder of Supernus, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote (2) to this Form 4.
- F3The option became exercisable in four equal installments beginning on February 5, 2014, which was the first anniversary of the date on which the option was granted.